Piracetam, Cinnarizine | Combitropil capsules, 30 pcs.

Release form

capsules

Packing

30 pcs.

Pharmacological action

Combitropil is a combined drug with a pronounced antihypoxic, nootropic and vasodilating effect.

Both components mutually potentiate their own antihypoxic effect and have a vasodilating effect. The combination drug also contributes to a significant increase in blood flow in the brain. The toxicity of the combination does not exceed the toxicity of the individual components of the drug.

Piracetam is a nootropic. It has a positive effect on the metabolic processes of the brain: it increases the concentration of ATP in the brain tissue, enhances the synthesis of RNA and phospholipids, stimulates glycolytic processes, and enhances glucose utilization.

Improves the integrative activity of the brain, promotes memory consolidation, facilitates the learning process.

Changes the rate of spread of excitation in the brain, improves microcirculation, without exerting a vasodilating effect, and inhibits the aggregation of activated platelets. It has a protective effect in case of brain damage caused by hypoxia, intoxication, electroshock enhances alpha and beta activity, reduces delta activity on the EEG, reduces the severity of vestibular nystagmus.

Improves interneuronal transmission and synaptic conduction in neocortical structures, increases mental performance, improves cerebral blood flow. The effect develops gradually.

Almost no sedative and psychostimulating effect.

Cinnarizine, a selective blocker of slow calcium channels, reduces Ca2 + entry into cells and reduces its content in the plasma membrane depot, reduces the tone of smooth muscles of arterioles, reduces their response to biogenic vasoconstrictor substances (epinephrine, norepinephrine, dopamine, angiotensin, vasopressin, serotonin).

It has a vasodilating effect (especially in relation to cerebral vessels, enhancing the antihypoxic effect of piracetam), without having a significant effect on blood pressure. It exhibits moderate antihistamine activity, reduces the excitability of the vestibular apparatus, and lowers the tone of the sympathetic nervous system. In patients with impaired peripheral circulation improves blood supply to organs and tissues (including myocardium), enhances postischemic vasodilation. Increases the elasticity of erythrocyte membranes, their ability to deform, reduces blood viscosity.

Pharmacokinetics

Combined drug is rapidly and completely absorbed in the gastrointestinal tract. The bioavailability of piracetam is 95%. The therapeutic effect appears after 1-6 hours. The maximum level of cinnarizine in plasma is noted after 1 -4 hours, piracetam - after 2-6 hours. Cinnarizine metabolism proceeds completely in the liver (by dealkylation). 60% of cinnarizine is excreted unchanged with feces, the rest with urine in the form of metabolites in about 5 hours. The maximum level of cinnarizine after 1-4 hours is noted not only in the blood, but also in the liver, kidneys, heart, lungs, spleen and brain. It binds to 91% with plasma proteins.

Piracetam crosses the blood-brain barrier, accumulates in the brain tissue 1-4 hours after ingestion. It is removed from the cerebrospinal fluid much more slowly than from other tissues. Virtually not metabolized. The elimination half-life is 4.5 hours (7.7 hours from the brain). It is excreted by the kidneys - 2/3 unchanged for 30 hours.

Contraindications

hypersensitivity

severe liver failure

severe renal failure

parkinsonism

pregnancy

lactation

children under 5 years of age.

Precautions: Parkinson's disease

renal and / or liver failure.

Special instructions

During treatment, monitoring of liver function is necessary.

At the beginning of treatment, the patient should refrain from drinking alcohol.

Due to the content of cinnarizine, the drug may cause a positive reaction in athletes during the doping test.

The drug should be carefully prescribed with increased intraocular pressure.

During treatment, care must be taken when driving and engaging in activities that require increased concentration of attention and speed of psychomotor reactions.

Composition

1 capsule contains: active substances: cinnarizine - 25 mg, piracetam - 400 mg.

excipients: microcrystalline cellulose, lactose (milk sugar), magnesium stearate, talc.

gelatin capsule composition: titanium dioxide, methyl parahydroxybenzoate, propyl parahydroxybenzoate, acetic acid, gelatin.

Dosage and administration

Combitropil is taken orally.

Adults - 1-2 caps. 3 times a day for 1-3 months, depending on the severity of the disease.

Children over the age of 5 years - 1-2 caps. 1-2 times a day for 1-3 months.

Treatment courses are carried out 2-3 times a year.

For chronic renal failure (Cl creatinine

Side effects

From the central nervous system and peripheral nervous system: irritability, sleep disturbance, naked severe pain, tremor of the extremities

From the digestive system: dyspepsia, epigastric pain, dry mouth.

Allergic reactions: skin rash.

Drug Interactions

Combitropil enhances the effects of drugs that inhibit the central nervous system, ethanol, as well as nootropic and antihypertensive drugs.

Improves tolerance to antipsychotic drugs (antipsychotics) and tricyclic antidepressants.

Vasodilating drugs enhance the effects of Combitropil.

Storage conditions

In the dark place at a temperature of no higher than 25 РC.

Expiration

2 years.

Deystvuyuschee substances

Piracetam, cinnarizine

Form of Treatment

kapsul

Synthesis AKOMP, Russia